Galderma Group AG (GDERF)

OTCMKTS · Delayed Price · Currency is USD
142.40
0.00 (0.00%)
Jul 3, 2025, 4:00 PM EDT
64.62%
Market Cap 35.11B
Revenue (ttm) 4.44B
Net Income (ttm) 231.00M
Shares Out n/a
EPS (ttm) 0.97
PE Ratio 151.98
Forward PE 49.95
Dividend 0.18 (0.13%)
Ex-Dividend Date Apr 25, 2025
Volume n/a
Average Volume 1,507
Open 142.40
Previous Close 142.40
Day's Range 142.40 - 142.40
52-Week Range 81.32 - 143.16
Beta n/a
RSI 87.58
Earnings Date Jul 24, 2025

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic ... [Read more]

Sector Healthcare
Founded 1981
Employees 6,545
Stock Exchange OTCMKTS
Ticker Symbol GDERF
Full Company Profile

Financial Performance

Financial Statements

News

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of ...

10 days ago - Business Wire

Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

Strategic move aims to accelerate innovation and growth in the U.S., Galderma's largest region MIAMI , June 17, 2025 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, to...

18 days ago - PRNewsWire